2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07F.08 Clinical Significance of Endothelial Programmed Cell Death Ligand 1 Expression in Patients with Non-Small Cell Lung Cancer

EP.07F.08 Clinical Significance of Endothelial Programmed Cell Death Ligand 1 Expression in Patients with Non-Small Cell Lung Cancer

Back to course

Pdf Summary

The study explores the clinical relevance of programmed cell death ligand 1 (PD-L1) expression on endothelial cells (EC) in patients with non-small cell lung cancer (NSCLC), focusing primarily on its potential impact on patient outcomes. PD-L1, widely studied for its role in tumor immune evasion, is present on both tumor cells and endothelial cells, the latter of which is less understood in the context of NSCLC.<br /><br />Out of 564 NSCLC cases (from 2009 to 2015), 395 were analyzed for PD-L1 on ECs using the 22C3 antibody. Only 10 cases showed PD-L1 presence on ECs. These patients generally exhibited higher body mass indices (BMI), advanced cancer stages, and increased vascular invasion compared to patients without PD-L1 EC expression. Notably, PD-L1 EC presence was statistically associated with poorer recurrence-free survival (RFS) but not with overall survival. <br /><br />The results suggest PD-L1 expression on ECs could be a predictor for poor RFS, indicating potential immune evasion facilitation. Despite these findings, statistical models such as the Cox Proportional Hazards Model showed PD-L1 ECs were not significantly linked with overall survival, although they were connected to shorter RFS.<br /><br />Limitations of this study include its retrospective nature, small sample size, and focus on a single institution, which restrict the generalizability of the results. Further studies are necessary to substantiate these findings and clarify the underlying mechanisms, including trialing targeted therapies such as anlotinib or osimertinib that may affect pathways involving PD-L1 EC expression.<br /><br />The study concludes that while PD-L1 endothelial expression confers worse RFS outcomes, more research is necessary to establish robust clinical application and investigate specific interventions.

Asset Subtitle

Tomohito Saito

Meta Tag

Speaker Tomohito Saito

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

PD-L1

endothelial cells

non-small cell lung cancer

NSCLC

patient outcomes

immune evasion

recurrence-free survival

Cox Proportional Hazards Model

targeted therapies

anlotinib